[go: up one dir, main page]

CN116286726A - A low-preference DNA fragmentation enzyme composition and its reaction solution - Google Patents

A low-preference DNA fragmentation enzyme composition and its reaction solution Download PDF

Info

Publication number
CN116286726A
CN116286726A CN202310263158.7A CN202310263158A CN116286726A CN 116286726 A CN116286726 A CN 116286726A CN 202310263158 A CN202310263158 A CN 202310263158A CN 116286726 A CN116286726 A CN 116286726A
Authority
CN
China
Prior art keywords
reaction solution
enzyme composition
dna polymerase
content
endonuclease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310263158.7A
Other languages
Chinese (zh)
Inventor
曹振
曲文茹
秦雪梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yisheng Biotechnology Shanghai Co ltd
Original Assignee
Yisheng Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yisheng Biotechnology Shanghai Co ltd filed Critical Yisheng Biotechnology Shanghai Co ltd
Priority to CN202310263158.7A priority Critical patent/CN116286726A/en
Publication of CN116286726A publication Critical patent/CN116286726A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1229Phosphotransferases with a phosphate group as acceptor (2.7.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241Nucleotidyltransferases (2.7.7)
    • C12N9/1252DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention discloses an enzyme composition for low-preference DNA fragmentation and a reaction solution thereof. The enzyme composition comprises endonuclease, nucleotide kinase and DNA polymerase, wherein the endonuclease comprises any one or a combination of at least two of DNase I, thermostable high salt endonuclease HL-SAN or endonuclease IV, the nucleotide kinase comprises T4 polynucleotide kinase, and the DNA polymerase comprises any one or a combination of at least two of Taq DNA polymerase, klenow fragment of DNA polymerase I or T4DNA polymerase. The invention develops a module suitable for genome fragmentation, end repair and A tail addition by a one-tube method, comprises an enzyme composition and a reaction solution thereof, aims at the problems and the defects existing in the current enzyme method library establishment, and aims at the problems and the defects of the enzyme method library establishment, and the problems are solved by optimizing and exploring each component and matching with a proper connecting module.

Description

一种低偏好性DNA片段化的酶组合物及其反应液A low-preference DNA fragmentation enzyme composition and its reaction solution

技术领域technical field

本发明属于生物技术领域,涉及一种低偏好性DNA片段化的酶组合物及其反应液。The invention belongs to the field of biotechnology, and relates to an enzyme composition for DNA fragmentation with low preference and a reaction liquid thereof.

背景技术Background technique

近几十年间,DNA测序技术被应用于分子生物学相关研究当中,极大的推进了该领域的快速发展。虽然一代DNA测序技术高达1000bp的读长和99.99%的准确性帮助研究者完成了大量的测序工作,但一代测序速度慢、成本高和通量低等方面的不足难以支撑测序需求的增长。第二代测序(Next-generation sequencing,NGS)又称为高通量测序(High-throughput sequencing,HTS),因其具有低成本、高通量等优点,被逐渐广泛应用于科学研究和临床实践等领域。In recent decades, DNA sequencing technology has been applied to molecular biology-related research, which has greatly promoted the rapid development of this field. Although the first-generation DNA sequencing technology has a read length of up to 1000bp and an accuracy of 99.99% to help researchers complete a large amount of sequencing work, the shortcomings of the first-generation sequencing technology, such as slow speed, high cost and low throughput, are difficult to support the growth of sequencing demand. Next-generation sequencing (NGS), also known as high-throughput sequencing (HTS), has been widely used in scientific research and clinical practice because of its low cost and high throughput. and other fields.

第二代测序的主要流程分为三部分,包括文库构建、基因测序和生信分析。其中,文库构建作为NGS测序的初始步骤,产出的文库对于最终的测序结果有着重要的影响,因此,做好文库构建提高文库质量显得尤为重要。基于二代测序的短读长特性,DNA文库构建的第一步需要将宏基因组片段化,目前有机械法和片段化酶法可以完成基因组DNA的打断。相较于传统机械法打断对于设备的过高要求和较长的操作时间,片段化酶法打断以其操作简便、时间短成本低等优点得到越来越广泛的应用。The main process of second-generation sequencing is divided into three parts, including library construction, gene sequencing and bioinformatics analysis. Among them, library construction is the initial step of NGS sequencing, and the generated library has an important impact on the final sequencing results. Therefore, it is particularly important to do a good job in library construction to improve the quality of the library. Based on the short read length characteristics of next-generation sequencing, the first step in DNA library construction needs to fragment the metagenomic group. Currently, there are mechanical methods and fragmentation enzyme methods that can complete the fragmentation of genomic DNA. Compared with the high requirements for equipment and long operating time of the traditional mechanical method, fragmentation enzymatic method has been widely used due to its advantages of simple operation, short time and low cost.

但与传统机械打断法的无偏好性随机切割相比,片段化酶打断法会有偏好性的选择DNA双链上的酶切位点进行切割,这就导致了文库中随机片段的丰度和多样性降低,产出的文库均一性较差,会使基因上的不同区域测序深度产生较大偏差,从而在测序时部分丰度较低的基因位点比较难检出,可能会出现漏检的情况。使用加大测序深度的方式可以减少漏检位点,但又会造成大量的数据浪费。However, compared with the unbiased random cutting of the traditional mechanical fragmentation method, the fragmentation enzyme fragmentation method will preferentially select the enzyme cutting site on the DNA double strand for cutting, which leads to the abundance of random fragments in the library. The degree and diversity of the library are reduced, and the uniformity of the output library is poor, which will cause large deviations in the sequencing depth of different regions of the gene, so that some gene loci with low abundance are difficult to detect during sequencing, and may occur The case of missed detection. Using the method of increasing the sequencing depth can reduce the missed detection sites, but it will cause a lot of data waste.

综上所述,目前片段化酶打断法存在文库中随机片段的丰度和多样性低,产出的文库均一性较差,基因上的不同区域测序深度存在较大偏差,在测序时部分丰度较低的基因位点难以检出,存在漏检等问题。提供一种用于DNA片段化的酶组合物及其反应液,适用于一管法基因组片段化、末端修复和加A尾模块,获得具有低偏好性,产出均一性更高的文库,已成为目前生物技术领域亟待解决的问题之一。In summary, the current fragmentation enzyme fragmentation method has low abundance and diversity of random fragments in the library, poor uniformity of the output library, and large deviations in the sequencing depth of different regions of the gene. Gene loci with low abundance are difficult to detect, and there are problems such as missed detection. Provides an enzyme composition for DNA fragmentation and its reaction solution, suitable for one-tube genome fragmentation, end repair and A-tailing modules, to obtain a library with low bias and higher output uniformity, and has been It has become one of the urgent problems to be solved in the field of biotechnology.

发明内容Contents of the invention

针对现有技术的不足和实际需求,本发明提供一种低偏好性DNA片段化的酶组合物及其反应液,解决了目前片段化酶打断法存在的文库中随机片段的丰度和多样性低,产出的文库均一性较差,基因上的不同区域测序深度存在较大偏差,在测序时部分丰度较低的基因位点难以检出,存在漏检等问题。本发明提供的酶组合物及其反应液通用性好,适用于各种的类型的二代测序反应。Aiming at the deficiencies and actual needs of the prior art, the present invention provides a low-preference DNA fragmentation enzyme composition and its reaction solution, which solves the problem of the abundance and diversity of random fragments in the library existing in the current fragmentation enzyme fragmentation method. The uniformity of the library is low, the uniformity of the output library is poor, there is a large deviation in the sequencing depth of different regions of the gene, and some gene loci with low abundance are difficult to detect during sequencing, and there are problems such as missed detection. The enzyme composition and its reaction solution provided by the invention have good versatility and are suitable for various types of next-generation sequencing reactions.

为达到此发明目的,本发明采用以下技术方案:To achieve this purpose of the invention, the present invention adopts the following technical solutions:

第一方面,本发明提供了一种低偏好性DNA片段化的酶组合物,所述酶组合物包括核酸内切酶、核苷酸激酶和DNA聚合酶,所述核酸内切酶包括DNaseⅠ、热不稳定性耐高盐核酸内切酶HL-SAN或核酸内切酶Ⅳ中的任意一种或至少两种的组合,所述核苷酸激酶包括T4多聚核苷酸激酶,所述DNA聚合酶包括Taq DNA聚合酶、DNA聚合酶Ⅰ的Klenow片段或T4 DNA聚合酶中的任意一种或至少两种的组合。In a first aspect, the present invention provides an enzyme composition for DNA fragmentation with low preference, the enzyme composition includes endonuclease, nucleotide kinase and DNA polymerase, and the endonuclease includes DNaseI, Any one or a combination of at least two of thermolabile high-salt-resistant endonuclease HL-SAN or endonuclease IV, said nucleotide kinase comprising T4 polynucleotide kinase, said DNA The polymerase includes any one or a combination of at least two of Taq DNA polymerase, Klenow fragment of DNA polymerase I or T4 DNA polymerase.

本发明开发了适用于一管法基因组片段化、末端修复、5’磷酸化和3’加A尾模块,包括酶组合物及其反应液,能够降低DNA片段化的偏好性,针对目前酶法建库存在的问题和不足,通过对各组分进行优化探究,搭配合适的连接模块,最终获得的产品具有低偏好性,产出均一性更高的文库,在二代测序中具有广阔的应用前景。The invention develops a module suitable for one-tube genome fragmentation, end repair, 5' phosphorylation and 3' adding A tail, including an enzyme composition and its reaction solution, which can reduce the preference of DNA fragmentation, and is aimed at the current enzymatic method Problems and deficiencies in library construction, through optimization and exploration of each component, with a suitable connection module, the final product obtained has low preference, and a library with higher output uniformity, which has a wide range of applications in next-generation sequencing prospect.

优选的,所述酶组合物包括以下组合物中的任意一种:Preferably, the enzyme composition comprises any one of the following compositions:

(1)DNaseⅠ、Taq DNA聚合酶、DNA聚合酶Ⅰ的Klenow片段和T4多聚核苷酸激酶的组合物;(1) Compositions of DNase I, Taq DNA polymerase, Klenow fragment of DNA polymerase I and T4 polynucleotide kinase;

(2)热不稳定性耐高盐核酸内切酶HL-SAN、Taq DNA聚合酶、DNA聚合酶Ⅰ的Klenow片段和T4多聚核苷酸激酶的组合物;(2) Compositions of heat-labile high-salt-resistant endonuclease HL-SAN, Taq DNA polymerase, Klenow fragment of DNA polymerase I and T4 polynucleotide kinase;

(3)DNaseⅠ、核酸内切酶Ⅳ、Taq DNA聚合酶、DNA聚合酶Ⅰ的Klenow片段、T4 DNA聚合酶和T4多聚核苷酸激酶的组合物。(3) Composition of DNase I, endonuclease IV, Taq DNA polymerase, Klenow fragment of DNA polymerase I, T4 DNA polymerase and T4 polynucleotide kinase.

优选的,所述酶组合物中DNaseⅠ的浓度为0.1-3U/μL。Preferably, the concentration of DNase I in the enzyme composition is 0.1-3 U/μL.

上述0.1-3中的具体点值可以选择0.1、0.5、1、1.5、2、2.5、3等。The specific point values in the above 0.1-3 can be selected from 0.1, 0.5, 1, 1.5, 2, 2.5, 3 and so on.

优选的,所述酶组合物中热不稳定性耐高盐核酸内切酶HL-SAN的浓度为0.01-3U/μL。Preferably, the concentration of the heat-labile high-salt-tolerant endonuclease HL-SAN in the enzyme composition is 0.01-3 U/μL.

上述0.01-3中的具体点值可以选择0.01、0.05、0.08、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、1.9、2、2.2、2.5、2.7、2.8、3等。The specific point values in the above 0.01-3 can be selected as 0.01, 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 1.9, 2, 2.2, 2.5, 2.7, 2.8, 3, etc.

优选的,所述酶组合物中核酸内切酶Ⅳ的浓度0.005-2U/μL。Preferably, the concentration of endonuclease IV in the enzyme composition is 0.005-2 U/μL.

上述0.005-2中的具体点值可以选择0.005、0.008、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1、1.2、1.5、1.7、1.8、2等。The specific point value in the above 0.005-2 can be selected as 0.005, 0.008, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.2, 1.5, 1.7, 1.8, 2, etc.

优选的,所述酶组合物中Taq DNA聚合酶的浓度2-35U/μL。Preferably, the concentration of Taq DNA polymerase in the enzyme composition is 2-35U/μL.

上述2-35中的具体点值可以选择2、6、9、12、20、25、29、30、31、32、33、34、35等。The specific point values in the above 2-35 can be selected from 2, 6, 9, 12, 20, 25, 29, 30, 31, 32, 33, 34, 35, etc.

优选的,所述酶组合物中DNA聚合酶Ⅰ的Klenow片段的浓度为0.01-7.8U/μL。Preferably, the concentration of the Klenow fragment of DNA polymerase I in the enzyme composition is 0.01-7.8 U/μL.

上述0.01-7.8中的具体点值可以选择0.01、0.05、0.08、0.1、0.2、0.3、0.4、0.5、0.6、1.7、2.8、3.9、4、5、6、7、7.8等。The specific point value in the above 0.01-7.8 can be selected as 0.01, 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 1.7, 2.8, 3.9, 4, 5, 6, 7, 7.8 and so on.

优选的,所述酶组合物中T4 DNA聚合酶的浓度0.3-40U/μL。Preferably, the concentration of T4 DNA polymerase in the enzyme composition is 0.3-40U/μL.

上述0.3-40中的具体点值可以选择0.3、0.5、1、2、3、8、10、20、30、32、33、34、36、38、39、40等。The specific point value in the above-mentioned 0.3-40 can be selected as 0.3, 0.5, 1, 2, 3, 8, 10, 20, 30, 32, 33, 34, 36, 38, 39, 40, etc.

优选的,所述酶组合物中T4多聚核苷酸激酶的浓度为0.1-3U/μL。Preferably, the concentration of T4 polynucleotide kinase in the enzyme composition is 0.1-3 U/μL.

上述0.1-3中的具体点值可以选择0.2、0.5、1、1.5、2.5等。The specific point values in the above 0.1-3 can be selected as 0.2, 0.5, 1, 1.5, 2.5, etc.

第二方面,本发明提供了一种酶组合物的反应液,所述反应液包括:二糖和/或二糖衍生物。In a second aspect, the present invention provides a reaction solution of an enzyme composition, the reaction solution comprising: disaccharides and/or disaccharide derivatives.

本发明反应液中二糖或二糖衍生物能够维持蛋白的结构稳定性,增强酶的蛋白功能结构域非特异性识别切割DNA双链上的位点的能力,能够促进酶组合物之间的协同作用,进一步降低产生文库的偏好性。The disaccharide or disaccharide derivatives in the reaction liquid of the present invention can maintain the structural stability of the protein, enhance the ability of the protein functional domain of the enzyme to non-specifically recognize and cut the site on the DNA double strand, and can promote the synergy between enzyme compositions effect, further reducing the bias of library generation.

优选地,所述二糖包括蔗糖。Preferably, the disaccharide comprises sucrose.

优选地,所述二糖衍生物包括水苏糖。Preferably, the disaccharide derivatives include stachyose.

优选的,所述反应液中蔗糖的浓度为50-120mM。Preferably, the concentration of sucrose in the reaction solution is 50-120mM.

上述50-120中的具体点值可以选择50、60、70、80、90、100、110、120等。You can choose 50, 60, 70, 80, 90, 100, 110, 120, etc. for the specific point value in the above-mentioned 50-120.

优选地,所述反应液中水苏糖的浓度为30-80mM。Preferably, the concentration of stachyose in the reaction solution is 30-80mM.

上述30-80中的具体点值可以选择30、40、50、60、70、80等。The specific point value in the above-mentioned 30-80 can choose 30, 40, 50, 60, 70, 80, etc.

优选地,所述反应液还包括缓冲液、金属盐离子、去垢剂、ATP、dATP和dNTP。Preferably, the reaction solution further includes buffer, metal salt ions, detergent, ATP, dATP and dNTP.

优选地,所述缓冲液包括三羟甲基氨基甲烷醋酸盐、三羟甲基氨基甲烷盐酸盐或4-羟乙基哌嗪乙磺酸中的任意一种或至少两种的组合。Preferably, the buffer solution includes any one or a combination of at least two of tris(hydroxymethylaminomethane) acetate, tris(hydroxymethylaminomethane) hydrochloride or 4-hydroxyethylpiperazineethanesulfonic acid.

优选的,所述反应液中三羟甲基氨基甲烷醋酸盐的含量为50-200mM,pH为7-8.5。Preferably, the content of Tris in the reaction solution is 50-200mM, and the pH is 7-8.5.

上述50-200中的具体点值可以选择50、60、70、80、90、100、110、120、130、140、150、190、200等。50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 190, 200, etc. can be selected for the specific point value in the above-mentioned 50-200.

优选的,所述反应液中三羟甲基氨基甲烷盐酸盐的含量为100-150mM,pH为7-9。Preferably, the content of tris hydrochloride in the reaction solution is 100-150 mM, and the pH is 7-9.

上述7-9中的具体点值可以选择7、8、9等。You can choose 7, 8, 9, etc. for the specific point value in the above 7-9.

上述100-150中的具体点值可以选择100、110、120、130、140、150等。You can choose 100, 110, 120, 130, 140, 150, etc. for the specific point value in the above-mentioned 100-150.

优选的,优选地,所述反应液中4-羟乙基哌嗪乙磺酸的含量为100-180mM,pH为7-9。Preferably, preferably, the content of 4-hydroxyethylpiperazineethanesulfonic acid in the reaction solution is 100-180 mM, and the pH is 7-9.

上述7-9中的具体点值可以选择7、8、9等。You can choose 7, 8, 9, etc. for the specific point value in the above 7-9.

上述100-180中的具体点值可以选择100、110、120、130、140、150、160、180等。The specific point value in the above 100-180 can be selected as 100, 110, 120, 130, 140, 150, 160, 180 and so on.

优选的,所述金属盐离子包括CaCl2、MgCl2、ZnCl2、NaCl或KCl中的任意一种或至少两种的组合。Preferably, the metal salt ions include any one or a combination of at least two of CaCl 2 , MgCl 2 , ZnCl 2 , NaCl or KCl.

优选的,所述反应液中CaCl2的含量为15-50mM。Preferably, the content of CaCl2 in the reaction solution is 15-50mM.

上述20-50中的具体点值可以选择15、30、40、50等。The specific point value in the above 20-50 can be selected as 15, 30, 40, 50 and so on.

优选的,所述反应液中MgCl2的含量为35-200mM。Preferably, the content of MgCl 2 in the reaction solution is 35-200mM.

上述50-200中的具体点值可以选择35、60、70、80、90、100、110、120、130、140、150、190、200等。The specific point values in the above 50-200 can be selected from 35, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 190, 200 and so on.

优选的,所述反应液中ZnCl2的含量为20-80mM。Preferably, the content of ZnCl 2 in the reaction solution is 20-80mM.

上述20-80中的具体点值可以选择20、30、40、50、60、70、80等。The specific point value in the above-mentioned 20-80 can choose 20, 30, 40, 50, 60, 70, 80 and so on.

优选的,所述反应液中NaCl的含量为20-200mM。Preferably, the content of NaCl in the reaction solution is 20-200mM.

上述20-200中的具体点值可以选择20、60、70、80、90、100、110、120、130、140、150、190、200等。The specific point value in the above-mentioned 20-200 can choose 20, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 190, 200 and so on.

优选的,所述反应液中KCl的含量为30-80mM。Preferably, the content of KCl in the reaction solution is 30-80mM.

上述30-80中的具体点值可以选择30、40、50、60、70、80等。The specific point value in the above-mentioned 30-80 can choose 30, 40, 50, 60, 70, 80, etc.

优选的,所述去垢剂包括DTT、TritonⅩ-100、Tween-20或NP-40中的任意一种或至少两种的组合。Preferably, the detergent includes any one or a combination of at least two of DTT, Triton X-100, Tween-20 or NP-40.

优选的,所述反应液中DTT的含量为10-50mM。Preferably, the content of DTT in the reaction solution is 10-50mM.

上述10-50中的具体点值可以选择10、20、30、40、50等。You can choose 10, 20, 30, 40, 50, etc. for the specific point value in the above-mentioned 10-50.

优选的,所述反应液中TritonⅩ-100的含量为0.1-1%。Preferably, the content of Triton X-100 in the reaction solution is 0.1-1%.

上述0.1-1中的具体点值可以选择0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1等。The specific point value in the above 0.1-1 can be selected as 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 and so on.

优选的,所述反应液中Tween-20的含量为0.01-1%。Preferably, the content of Tween-20 in the reaction solution is 0.01-1%.

上述0.01-1中的具体点值可以选择0.01、0.05、0.08、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1等。The specific point value in the above 0.01-1 can be selected as 0.01, 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 and so on.

优选的,所述反应液中NP-40的含量为0.01-1%。Preferably, the content of NP-40 in the reaction solution is 0.01-1%.

上述0.01-1中的具体点值可以选择0.01、0.05、0.08、0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1等。The specific point value in the above 0.01-1 can be selected as 0.01, 0.05, 0.08, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 and so on.

优选的,所述反应液中dATP的含量为0.2-8mM,优选为2-4mM。Preferably, the content of dATP in the reaction solution is 0.2-8mM, preferably 2-4mM.

上述0.2-8中的具体点值可以选择0.2、0.3、0.4、1、2、3、4、5、6、7、8等。The specific point values in the above 0.2-8 can be selected from 0.2, 0.3, 0.4, 1, 2, 3, 4, 5, 6, 7, 8, etc.

上述2-4中的具体点值可以选择2、3、4等。The specific point values in the above 2-4 can be selected as 2, 3, 4, etc.

所述反应液中dNTP的含量为0.02-2mM,优选为0.02-1mM。The content of dNTP in the reaction solution is 0.02-2mM, preferably 0.02-1mM.

上述0.02-2中的具体点值可以选择0.02、0.03、0.4、0.8、1、1.3、1.4、1.5、1.6、1.7、1.8、1.9、2等。The specific point values in the above 0.02-2 can be selected as 0.02, 0.03, 0.4, 0.8, 1, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, etc.

所述反应液中ATP的含量为5-15mM。The content of ATP in the reaction solution is 5-15mM.

上述5-10中的具体点值可以选择5、6、7、8、9、10、11、15等。The specific point values in the above 5-10 can be selected as 5, 6, 7, 8, 9, 10, 11, 15 and so on.

第三方面,本发明提供了一种构建测序文库的方法,所述方法包括:将靶核酸加入如第一方面所述的酶组合物和第二方面所述的反应液的混合液中,孵育,进行靶核酸的片段化、末端修复、5’磷酸化和3’加A尾。In a third aspect, the present invention provides a method for constructing a sequencing library, the method comprising: adding the target nucleic acid to the mixture of the enzyme composition as described in the first aspect and the reaction solution as described in the second aspect, and incubating , for target nucleic acid fragmentation, end repair, 5' phosphorylation, and 3' A-tailing.

第四方面,本发明提供了一种用于构建测序文库的试剂盒,所述试剂盒包括第一方面所述的酶组合物或第二方面所述的反应液。In a fourth aspect, the present invention provides a kit for constructing a sequencing library, the kit including the enzyme composition described in the first aspect or the reaction solution described in the second aspect.

优选地,所述试剂盒还包括测序接头和连接反应试剂。Preferably, the kit also includes sequencing adapters and ligation reagents.

与现有技术相比,本发明具有如下有益效果:Compared with the prior art, the present invention has the following beneficial effects:

(1)本发明开发的一管法基因组片段化、末端修复和加A尾模块,包括酶组合物及其反应液,针对目前酶法建库存在的问题和不足,通过对各组分进行优化探究,搭配连接模块使用,并通过对待测DNA样本完成二代测序全流程实验,从最终测序结果来验证本发明提供的酶组合物及其反应液的效果,进一步证实了其在二代测序的生产中具有切实的应用价值。(1) The one-tube genome fragmentation, end repair and A-tailing modules developed by the present invention, including the enzyme composition and its reaction solution, aim at the problems and deficiencies of the current enzymatic library construction, by optimizing each component Exploration, used with the connection module, and through the completion of the whole process of next-generation sequencing experiments on the DNA samples to be tested, the effects of the enzyme composition and its reaction solution provided by the present invention are verified from the final sequencing results, further confirming its role in next-generation sequencing It has practical application value in production.

(2)本发明提供的方案,通用性好,适用于各种的类型的二代测序反应。在PCRfree文库的构建应用中,靶基因经过片段化、末端修复和加A和接头连接反应两个步骤得到的未经PCR扩增的文库。构建PCR free文库进行测序的好处是更加快速高效,并且可以避免PCR扩增带来的保真性差等问题,本发明提供的酶组合物及其反应液解决了在PCR free建库的过程中,高投入量下酶切位点偏好性和GC偏好性高问题。(2) The scheme provided by the present invention has good versatility and is applicable to various types of next-generation sequencing reactions. In the application of PCRfree library construction, the target gene undergoes two steps of fragmentation, end repair, addition of A and linker ligation to obtain a non-PCR-amplified library. The advantage of constructing a PCR free library for sequencing is that it is faster and more efficient, and can avoid problems such as poor fidelity caused by PCR amplification. The enzyme composition and its reaction solution provided by the present invention solve the problem of High input restriction site preference and high GC preference.

附图说明Description of drawings

图1为实施例1酶切建库测序reads碱基分布图;Fig. 1 is the base distribution figure of embodiment 1 restriction enzyme digestion library construction sequencing reads;

图2为实施例2酶切建库测序reads碱基分布图;Fig. 2 is the base distribution figure of embodiment 2 enzyme digestion library construction sequencing reads;

图3为实施例3酶切建库测序reads碱基分布图;Fig. 3 is the base distribution figure of embodiment 3 enzyme digestion library construction sequencing reads;

图4为实施例4酶切建库测序reads碱基分布图;Fig. 4 is the base distribution figure of embodiment 4 restriction endonuclease library construction sequencing reads;

图5为实施例5酶切建库测序reads碱基分布图;Fig. 5 is the base distribution figure of embodiment 5 enzyme digestion library construction sequencing reads;

图6为实施例6酶切建库测序reads碱基分布图;Fig. 6 is the base distribution figure of embodiment 6 enzyme digestion library construction sequencing reads;

图7为12619酶切建库测序reads碱基分布图;Figure 7 is the base distribution map of 12619 enzyme digestion library construction and sequencing reads;

图8为实施例1酶切建库测序不同GC区域覆盖度分布图;Fig. 8 is the coverage distribution diagram of different GC regions for enzyme digestion library construction and sequencing in Example 1;

图9为实施例2酶切建库测序不同GC区域覆盖度分布图;Figure 9 is a distribution map of the coverage of different GC regions for enzyme digestion library construction and sequencing in Example 2;

图10为实施例3酶切建库测序不同GC区域覆盖度分布图;Fig. 10 is the coverage distribution diagram of different GC regions for enzyme digestion library construction and sequencing in Example 3;

图11为实施例4酶切建库测序不同GC区域覆盖度分布图;Figure 11 is a distribution map of the coverage of different GC regions for enzyme digestion library construction and sequencing in Example 4;

图12为实施例5酶切建库测序不同GC区域覆盖度分布图;Figure 12 is a distribution map of the coverage of different GC regions for enzyme digestion library construction and sequencing in Example 5;

图13为实施例6酶切建库测序不同GC区域覆盖度分布图;Figure 13 is a distribution map of the coverage of different GC regions for enzyme digestion library construction and sequencing in Example 6;

图14为12619酶切建库测序不同GC区域覆盖度分布图。Figure 14 is the coverage distribution map of different GC regions for 12619 enzyme digestion library construction and sequencing.

具体实施方式Detailed ways

为进一步阐述本发明所采取的技术手段及其效果,以下结合实施例和附图对本发明作进一步地说明。可以理解的是,此处所描述的具体实施方式仅仅用于解释本发明,而非对本发明的限定。In order to further illustrate the technical means and effects adopted by the present invention, the present invention will be further described below in conjunction with the embodiments and accompanying drawings. It should be understood that the specific implementation manners described here are only used to explain the present invention, rather than to limit the present invention.

实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道商购获得的常规产品。If no specific technique or condition is indicated in the examples, it shall be carried out according to the technique or condition described in the literature in this field, or according to the product specification. The reagents or instruments used were not indicated by the manufacturer, and they were all conventional products commercially available through formal channels.

实施例涉及的蛋白酶来源如表1所示。The sources of proteases involved in the examples are shown in Table 1.

表1Table 1

Figure BDA0004132082990000091
Figure BDA0004132082990000091

实施例1Example 1

本实施例提供一种酶组合物及其反应液:DNaseⅠ1.5U/μL,Taq DNA聚合酶1U/μL,DNA聚合酶Ⅰ的Klenow片段2U/μL,T4多聚核苷酸激酶1U/μL,反应液:Tris-Acetate 75mMpH7.5,CaCl220 mM,MgCl245 mM,NaCl 20mM,ZnCl250 mM,TritonⅩ-1000.1%,Tween-200.01%,dATP 2mM,dNTP 0.2mM,ATP 9mM。This example provides an enzyme composition and its reaction solution: DNase I 1.5 U/μL, Taq DNA polymerase 1 U/μL, DNA polymerase I Klenow fragment 2 U/μL, T4 polynucleotide kinase 1 U/μL, Reaction solution: Tris-Acetate 75mM pH7.5, CaCl 2 20 mM, MgCl 2 45 mM, NaCl 20 mM, ZnCl 2 50 mM, Triton X-1000.1%, Tween-200.01%, dATP 2mM, dNTP 0.2mM, ATP 9mM.

实施例2Example 2

本实施例提供一种酶组合物及其反应液:热不稳定性耐高盐核酸内切酶HL-SAN0.5U/μL,Taq DNA聚合酶5U/μL,DNA聚合酶Ⅰ的Klenow片段2U/μL,T4多聚核苷酸激酶1U/μL;反应液:HEPES 120mM pH7.5,CaCl235 mM,MgCl235mM,NaCl 30mM,KCl 60mM,TritonⅩ-1000.1%,Tween-200.05%,NP-400.05%,dATP 2mM,dNTP 0.2mM,ATP 15mM。This example provides an enzyme composition and its reaction solution: heat-labile high-salt-tolerant endonuclease HL-SAN 0.5U/μL, Taq DNA polymerase 5U/μL, DNA polymerase I Klenow fragment 2U/μL μL, T4 polynucleotide kinase 1U/μL; reaction solution: HEPES 120mM pH7.5, CaCl 2 35 mM, MgCl 2 35mM, NaCl 30mM, KCl 60mM, TritonⅩ-1000.1%, Tween-200.05%, NP-400.05 %, dATP 2mM, dNTP 0.2mM, ATP 15mM.

实施例3Example 3

本实施例提供一种酶组合物及其反应液:DNaseⅠ1U/μL,核酸内切酶Ⅳ0.05U/μL,Taq DNA聚合酶9U/μL,DNA聚合酶Ⅰ的Klenow片段2U/μL,T4 DNA聚合酶0.5U/μL,T4多聚核苷酸激酶2U/μL;反应液:Tris-HCl 100mM pH7.5,CaCl215 mM,MgCl250 mM,NaCl 30mM,NP-400.02%,Tween-200.01%,dATP 2mM,dNTP 0.2mM,ATP 9mM。This embodiment provides an enzyme composition and its reaction solution: DNase I 1U/μL, endonuclease IV 0.05U/μL, Taq DNA polymerase 9U/μL, DNA polymerase I Klenow fragment 2U/μL, T4 DNA polymerase Enzyme 0.5U/μL, T4 polynucleotide kinase 2U/μL; reaction solution: Tris-HCl 100mM pH7.5, CaCl 2 15 mM, MgCl 2 50 mM, NaCl 30mM, NP-400.02%, Tween-200.01% , dATP 2mM, dNTP 0.2mM, ATP 9mM.

实施例4Example 4

本实施例提供一种酶组合物及其反应液:DNaseⅠ1.5U/μL,Taq DNA聚合酶1U/μL,DNA聚合酶Ⅰ的Klenow片段2U/μL,T4多聚核苷酸激酶1U/μL,反应液:蔗糖50mM,Tris-Acetate 75mM pH7.5,CaCl220 mM,MgCl245 mM,NaCl 20mM,ZnCl250 mM,TritonⅩ-1000.1%,Tween-200.01%,dATP 2mM,dNTP 0.2mM,ATP 9mM。本实施例与实施例1的区别仅在于:反应液中还添加蔗糖50mM。This example provides an enzyme composition and its reaction solution: DNase I 1.5 U/μL, Taq DNA polymerase 1 U/μL, DNA polymerase I Klenow fragment 2 U/μL, T4 polynucleotide kinase 1 U/μL, Reaction solution: sucrose 50mM, Tris-Acetate 75mM pH7.5, CaCl 2 20 mM, MgCl 2 45 mM, NaCl 20mM, ZnCl 2 50 mM, TritonⅩ-1000.1%, Tween-200.01%, dATP 2mM, dNTP 0.2mM, ATP 9mM. The difference between this example and Example 1 is that 50 mM sucrose is added to the reaction solution.

实施例5Example 5

本实施例提供一种酶组合物及其反应液:热不稳定性耐高盐核酸内切酶HL-SAN0.5U/μL,Taq DNA聚合酶5U/μL,DNA聚合酶Ⅰ的Klenow片段2U/μL,T4多聚核苷酸激酶2U/μL;反应液:蔗糖120mM,HEPES 120mM pH7.5,CaCl235 mM,MgCl235mM,NaCl 30mM,KCl 60mM,TritonⅩ-1000.1%,Tween-200.05%,NP-400.05%,dATP 2mM,dNTP 0.2mM,ATP 15mM。本实施例与实施例2的区别仅在于:反应液中还添加蔗糖120mM。This example provides an enzyme composition and its reaction solution: heat-labile hypersalt-resistant endonuclease HL-SAN 0.5U/μL, Taq DNA polymerase 5U/μL, DNA polymerase I Klenow fragment 2U/μL μL, T4 polynucleotide kinase 2U/μL; reaction solution: sucrose 120mM, HEPES 120mM pH7.5, CaCl 2 35 mM, MgCl 2 35mM, NaCl 30mM, KCl 60mM, TritonⅩ-1000.1%, Tween-200.05%, NP-400.05%, dATP 2mM, dNTP 0.2mM, ATP 15mM. The difference between this example and Example 2 is that 120 mM sucrose is added to the reaction solution.

实施例6Example 6

DNaseⅠ1U/μL,核酸内切酶Ⅳ0.05U/μL,Taq DNA聚合酶9U/μL,DNA聚合酶Ⅰ的Klenow片段2U/μL,T4 DNA聚合酶0.5U/μL,T4多聚核苷酸激酶12U/μL;反应液:水苏糖30mM,Tris-HCl 100mM pH7.5,CaCl215 mM,MgCl250mM,NaCl 30mM,NP-400.02%,Tween-200.01%,dATP 2mM,dNTP 0.2mM,ATP 9mM。本实施例与实施例3的区别仅在于:反应液中还添加水苏糖30mM。DNase Ⅰ 1U/μL, endonuclease Ⅳ 0.05U/μL, Taq DNA polymerase 9U/μL, DNA polymerase Ⅰ Klenow fragment 2U/μL, T4 DNA polymerase 0.5U/μL, T4 polynucleotide kinase 12U /μL; Reaction solution: stachyose 30mM, Tris-HCl 100mM pH7.5, CaCl 2 15 mM, MgCl 2 50mM, NaCl 30mM, NP-400.02%, Tween-200.01%, dATP 2mM, dNTP 0.2mM, ATP 9mM . The only difference between this example and Example 3 is that 30 mM stachyose is added to the reaction solution.

实施例7Example 7

构建PCR free测序文库。Construct PCR free sequencing library.

本实例以human female gDNA为模板,起始投入量为1000ng,使用实施例1-6中的不同酶组合物及其搭配的反应液对gDNA模板进行片段化/末端修复/5’磷酸化/3’加A尾,搭配翌圣生物

Figure BDA0004132082990000111
Rapid DNA Ligation Module for kit(#13580)和华大智造MGIEasyPFAdapters(#1000013460)进行接头连接反应,使用/>
Figure BDA0004132082990000112
Smarter DNAClean Beads(#12600)对接头连接产物进行纯化分选,获得可供测序的PCR free文库。In this example, human female gDNA is used as a template, and the initial input amount is 1000ng. Different enzyme compositions and matching reaction solutions in Examples 1-6 are used to fragment/end repair/5' phosphorylation/3 'Add A tail, with Yisheng creatures
Figure BDA0004132082990000111
Rapid DNA Ligation Module for kit (#13580) and MGI MGIEasyPFAdapters (#1000013460) for adapter ligation reaction, use />
Figure BDA0004132082990000112
Smarter DNAClean Beads (#12600) were used to purify and sort adapter ligation products to obtain a PCR free library for sequencing.

本实例还使用商业化翌圣生物

Figure BDA0004132082990000113
OnePot Pro DNA FragmentationReagent(#12619)进行对比。对gDNA模板进行片段化/末端修复/5’磷酸化/3’加A尾,搭配翌圣生物/>
Figure BDA0004132082990000114
Rapid DNA Ligation Module for kit(#13580)和华大智造MGIEasyPF Adapters(#1000013460)进行接头连接反应,使用翌圣生物/>
Figure BDA0004132082990000121
Smarter DNAClean Beads(#12600)对接头连接产物进行纯化分选,构建PCR free文库,具体操作步骤参考说明书。This example also uses the commercial Yisheng biological
Figure BDA0004132082990000113
OnePot Pro DNA FragmentationReagent (#12619) for comparison. Fragmentation/end repair/5'phosphorylation/3'adding A tail on gDNA template, with Yisheng Bio>
Figure BDA0004132082990000114
Rapid DNA Ligation Module for kit (#13580) and MGI MGIEasyPF Adapters (#1000013460) for linker ligation reaction, using Yisheng Biology/>
Figure BDA0004132082990000121
Smarter DNAClean Beads (#12600) was used to purify and sort adapter ligation products to construct a PCR free library. Please refer to the manual for specific operation steps.

靶DNA的片段化/末端修复/5’磷酸化/3’加A尾反应体系如表2所示,其中,酶组合物的配方分别采用实施例1-6,反应条件为30℃孵育15min、65℃孵育20min。The target DNA fragmentation/end repair/5' phosphorylation/3' plus A tail reaction system is shown in Table 2, wherein the formulations of the enzyme composition are respectively used in Examples 1-6, and the reaction conditions are incubation at 30°C for 15 minutes, Incubate at 65°C for 20min.

表2Table 2

组分components 用量Dosage 靶DNAtarget DNA 1000ng1000ng 酶组合物enzyme composition 5μL5μL 反应液The reaction solution 10μL10 μL 1×TE1×TE 补齐至60μLMake up to 60μL

将得到的片段化/末端修复/5’磷酸化/3’加A尾产物直接进行接头连接反应,反应体系如表3,反应条件为20℃孵育15min。The resulting fragmentation/end repair/5' phosphorylation/3' plus A tail product was directly subjected to the adapter ligation reaction, the reaction system was shown in Table 3, and the reaction conditions were incubation at 20°C for 15 minutes.

表3table 3

组分components 用量Dosage 片段化/末端修复/5’磷酸化/3’加A尾Fragmentation/end repair/5' phosphorylation/3' A-tailing 60μL60μL 连接反应缓冲液(Ligation Enhancer)Ligation Buffer (Ligation Enhancer) 30μL30μL MGIEasy PF AdaptersMGIEasy PF Adapters 5μL5μL 连接酶(Rapid T4 DNA Ligase2.0)Ligase (Rapid T4 DNA Ligase2.0) 5μL5μL

孵育后得到的接头连接产物使用

Figure BDA0004132082990000122
Smarter DNA Clean Beads进行分选,分选比例为0.7/0.2×,22μL无菌ddH2O洗脱,回收20μL,即为可供上机测序的PCRfree文库,测序使用MGI DNBSEQ-T7平台,模式为PE150。The adapter ligation products obtained after incubation were used
Figure BDA0004132082990000122
Smarter DNA Clean Beads were sorted, the sorting ratio was 0.7/0.2×, 22 μL sterile ddH 2 O was eluted, and 20 μL was recovered, which was the PCRfree library for sequencing on the machine. The sequencing used the MGI DNBSEQ-T7 platform, and the mode was PE150.

对测序数据进行分析,使用fastp 0.23.1过滤原始数据中包含接头序列和低质量的Reads,得到高质量的测序数据(Clean Reads),每个样本取相同Clean Reads数据量,使用FastQC 0.11.9分析选取后的Clean Reads,根据分析结果中的Perbase sequencecontent指标对应的碱基波动的大小作为酶切打断偏好性的指标,波动程度大,酶切打断偏好性越严重。实验分析结果如图1-7所示。Analyze the sequencing data, use fastp 0.23.1 to filter the original data containing adapter sequences and low-quality Reads, and obtain high-quality sequencing data (Clean Reads), each sample takes the same amount of Clean Reads data, using FastQC 0.11.9 After analyzing the selected Clean Reads, the size of base fluctuations corresponding to the Perbase sequencecontent index in the analysis results is used as an index of restriction restriction preference. The greater the fluctuation degree, the more serious restriction restriction is. The experimental analysis results are shown in Figure 1-7.

使用bwa0.7.17将选取的Clean Reads与hg38参考基因组进行比对,使用Samtools1.16.1对比对文件进行排序,使用picard.jar 1.86.0的Collect GC Bias Metrics模块分析基因组不同GC区域的覆盖度信息,根据展示的基因组不同GC区域覆盖度的结果判断酶切对于基因组不同GC含量区域的打断偏好。实验分析结果如图8-14所示。Use bwa0.7.17 to compare the selected Clean Reads with the hg38 reference genome, use Samtools1.16.1 to compare and sort the files, use the Collect GC Bias Metrics module of picard.jar 1.86.0 to analyze the coverage information of different GC regions of the genome, According to the displayed results of the coverage of different GC regions of the genome, the fragmentation preference of enzyme digestion for regions with different GC content of the genome can be judged. The experimental analysis results are shown in Figure 8-14.

结果:由图7可知翌圣生物

Figure BDA0004132082990000131
OnePot Pro DNA FragmentationReagent(#12619)酶切位点碱基波动值为4-50%;本发明中应用实施例1酶切位点碱基波动值为12-42%(图1),对应添加二糖的实施例4酶切位点碱基波动值为16%-38%(图4);实施例2酶切位点碱基波动值为16%-40%(图2),对应添加二糖的实施例5酶切位点碱基波动值为18%-39%(图5);实施例3酶切位点碱基波动值为15%-40%(图3),对应添加二糖衍生物的实施例6酶切位点碱基波动值为18%-36%(图6)。和/>
Figure BDA0004132082990000132
OnePot Pro DNAFragmentation Reagent(#12619)相比,本发明中的实施例在酶切位点偏好性上有很大程度的改善。其中实施例1-6选用不同的酶组合物结果酶切位点碱基波动减小,偏好性降低;进一步地,实施例4、实施例5、实施例6分别添加二糖或二糖衍生物结果比单纯酶组合物效果更好,酶切位点碱基波动进一步减小,偏好性进一步降低,实施例6选用的酶组合物及其反应液为最优选的组合,结果酶切位点碱基波动最小,偏好性最低。Result: From Figure 7, it can be seen that Yisheng biological
Figure BDA0004132082990000131
OnePot Pro DNA FragmentationReagent (#12619) has a base fluctuation value of 4-50% at the enzyme cutting site; in the present invention, the base fluctuation value of the enzyme cutting site in Example 1 is 12-42% (Figure 1), corresponding to adding two The base fluctuation value of the enzyme cutting site in Example 4 of the sugar is 16%-38% (Figure 4); the base fluctuation value of the enzyme cutting site in Example 2 is 16%-40% (Figure 2), corresponding to the addition of disaccharides The base fluctuation value of the enzyme cutting site in Example 5 is 18%-39% (Figure 5); the base fluctuation value of the enzyme cutting site in Example 3 is 15%-40% (Figure 3), corresponding to the addition of disaccharide derivatives The base fluctuation value of the enzyme cleavage site in Example 6 of the product is 18%-36% (FIG. 6). and />
Figure BDA0004132082990000132
Compared with OnePot Pro DNA Fragmentation Reagent (#12619), the embodiments of the present invention have greatly improved the restriction site preference. Among them, the selection of different enzyme compositions in Examples 1-6 results in reduced base fluctuations and reduced preferences for enzyme cleavage sites; further, in Example 4, Example 5, and Example 6, disaccharides or disaccharide derivatives are added respectively As a result, the effect is better than that of the simple enzyme composition, the base fluctuation of the restriction site is further reduced, and the preference is further reduced. The enzyme composition and its reaction solution selected in Example 6 are the most preferred combination. The base fluctuation is the smallest, and the preference is the lowest.

不同GC区域的覆盖度越接近平均值1,GC偏好性越小,均一性越好,实施例1-6的GC偏好性结果如图8-13所示。The closer the coverage of different GC regions is to the average value 1, the smaller the GC bias and the better the uniformity. The GC bias results of Examples 1-6 are shown in Figures 8-13.

结果:实施例1-6的GC偏好性结果(图8-图13)均好于翌圣生物

Figure BDA0004132082990000141
OnePot Pro DNAFragmentation Reagent(#12619)(图14)说明利用本发明的酶组合物及反应液能够最终获得具有低偏好性的DNA片段,产出的文库均一性更高,在二代测序中具有广阔的应用前景。其中实施例4的GC偏好性相较于实施例1结果更好,实施例5的GC偏好性相较于实施例2结果更好,实施例6的GC偏好性相较于实施例3结果更好。实施例6的GC偏好性最低,结果最好,说明实施例6的酶组合物及反应液能够最终获得具有低偏好性的DNA片段,产出的文库均一性最佳,在二代测序中具有广阔的应用前景。Results: The GC preference results of Examples 1-6 (Figure 8-Figure 13) are better than those of Yisheng Biology
Figure BDA0004132082990000141
OnePot Pro DNA Fragmentation Reagent (#12619) (Figure 14) shows that the use of the enzyme composition and reaction solution of the present invention can finally obtain DNA fragments with low preference, and the output library has higher uniformity, which has broad application potential in next-generation sequencing. application prospects. The GC preference of Example 4 is better than that of Example 1, the GC preference of Example 5 is better than that of Example 2, and the GC preference of Example 6 is better than that of Example 3. good. Example 6 has the lowest GC preference and the best result, indicating that the enzyme composition and reaction solution of Example 6 can finally obtain DNA fragments with low preference, and the output library has the best uniformity, and has the advantages in next-generation sequencing. Broad application prospects.

综上所述,在二代测序文库构建的流程中,第一步片段化、末端修复、加A尾反应对最终的文库质量起到非常重要的作用,本发明通过对该步骤的酶组合物及其对应的反应液进行探究,对各组分浓度、种类、数量进行协同优化,最终解决了高投入量下,酶切法建库产出的文库均一性差的问题,很大程度上降低了文库酶切位点偏好性和GC偏好性。并通过对待测DNA样本完成二代测序全流程实验,从最终测序结果来验证本发明提供的酶组合物及其反应液的效果,进一步证实了其在二代测序的生产中具有切实的应用价值。To sum up, in the process of next-generation sequencing library construction, the first step of fragmentation, end repair, and A tailing reaction plays a very important role in the quality of the final library. The present invention adopts the enzyme composition for this step and its corresponding reaction solution, and the synergistic optimization of the concentration, type, and quantity of each component finally solved the problem of poor uniformity of the library produced by the enzyme digestion method under high input, and greatly reduced the Library restriction site preference and GC preference. And by completing the whole process experiment of next-generation sequencing on the DNA sample to be tested, the effects of the enzyme composition and its reaction solution provided by the present invention are verified from the final sequencing results, which further proves that it has practical application value in the production of next-generation sequencing .

申请人声明,本发明通过上述实施例来说明本发明的详细方法,但本发明并不局限于上述详细方法,即不意味着本发明必须依赖上述详细方法才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品各原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。The applicant declares that the present invention illustrates the detailed methods of the present invention through the above-mentioned examples, but the present invention is not limited to the above-mentioned detailed methods, that is, it does not mean that the present invention must rely on the above-mentioned detailed methods to be implemented. Those skilled in the art should understand that any improvement of the present invention, the equivalent replacement of each raw material of the product of the present invention, the addition of auxiliary components, the selection of specific methods, etc., all fall within the scope of protection and disclosure of the present invention.

Claims (10)

1.一种低偏好性DNA片段化的酶组合物,其特征在于,所述酶组合物包括核酸内切酶、核苷酸激酶和DNA聚合酶;1. an enzyme composition of low preference DNA fragmentation, is characterized in that, described enzyme composition comprises endonuclease, nucleotide kinase and DNA polymerase; 所述核酸内切酶包括DNaseⅠ、热不稳定性耐高盐核酸内切酶HL-SAN或核酸内切酶Ⅳ中的任意一种或至少两种的组合;The endonuclease includes any one or a combination of at least two of DNase I, heat-labile high-salt-resistant endonuclease HL-SAN or endonuclease IV; 所述核苷酸激酶包括T4多聚核苷酸激酶;The nucleotide kinases include T4 polynucleotide kinases; 所述DNA聚合酶包括TaqDNA聚合酶、DNA聚合酶Ⅰ的Klenow片段或T4DNA聚合酶中的任意一种或至少两种的组合。The DNA polymerase includes any one or a combination of at least two of Taq DNA polymerase, Klenow fragment of DNA polymerase I or T4 DNA polymerase. 2.根据权利要求1所述的酶组合物,其特征在于,所述酶组合物包括以下组合物的任意一种:2. enzyme composition according to claim 1, is characterized in that, described enzyme composition comprises any one of following composition: (1)DNaseⅠ、TaqDNA聚合酶、DNA聚合酶Ⅰ的Klenow片段和T4多聚核苷酸激酶的组合物;(1) Compositions of DNase I, Taq DNA polymerase, Klenow fragment of DNA polymerase I and T4 polynucleotide kinase; (2)热不稳定性耐高盐核酸内切酶HL-SAN、TaqDNA聚合酶、DNA聚合酶Ⅰ的Klenow片段和T4多聚核苷酸激酶的组合物;(2) Compositions of thermolabile high-salt-resistant endonuclease HL-SAN, TaqDNA polymerase, Klenow fragment of DNA polymerase I and T4 polynucleotide kinase; (3)DNaseⅠ、核酸内切酶Ⅳ、TaqDNA聚合酶、DNA聚合酶Ⅰ的Klenow片段、T4DNA聚合酶和T4多聚核苷酸激酶的组合物。(3) Composition of DNase I, endonuclease IV, Taq DNA polymerase, Klenow fragment of DNA polymerase I, T4 DNA polymerase and T4 polynucleotide kinase. 3.根据权利要求1或2所述的酶组合物,其特征在于,所述酶组合物中DNaseⅠ的浓度为0.1-3U/μL;3. The enzyme composition according to claim 1 or 2, characterized in that, the concentration of DNase I in the enzyme composition is 0.1-3U/μL; 优选地,所述酶组合物中热不稳定性耐高盐核酸内切酶HL-SAN的浓度为0.01-3U/μL;Preferably, the concentration of the heat-labile high-salt-resistant endonuclease HL-SAN in the enzyme composition is 0.01-3U/μL; 优选地,所述酶组合物中核酸内切酶Ⅳ的浓度0.005-2U/μL;Preferably, the concentration of endonuclease IV in the enzyme composition is 0.005-2U/μL; 优选地,所述酶组合物中TaqDNA聚合酶的浓度2-35U/μL;Preferably, the concentration of TaqDNA polymerase in the enzyme composition is 2-35U/μL; 优选地,所述酶组合物中DNA聚合酶Ⅰ的Klenow片段的浓度为0.01-7.8U/μL;Preferably, the concentration of the Klenow fragment of DNA polymerase I in the enzyme composition is 0.01-7.8 U/μL; 优选地,所述酶组合物中T4DNA聚合酶的浓度0.3-40U/μL;Preferably, the concentration of T4 DNA polymerase in the enzyme composition is 0.3-40U/μL; 优选地,所述酶组合物中T4多聚核苷酸激酶的浓度为0.1-3U/μL。Preferably, the concentration of T4 polynucleotide kinase in the enzyme composition is 0.1-3 U/μL. 4.一种酶组合物的反应液,其特征在于,所述反应液包括:二糖和/或二糖衍生物;4. A reaction solution of an enzyme composition, characterized in that the reaction solution comprises: disaccharides and/or disaccharide derivatives; 优选地,所述二糖包括蔗糖;Preferably, the disaccharide comprises sucrose; 优选地,所述二糖衍生物包括水苏糖;Preferably, the disaccharide derivatives include stachyose; 优选地,所述反应液中蔗糖的浓度为50-120mM;Preferably, the concentration of sucrose in the reaction solution is 50-120mM; 优选地,所述反应液中水苏糖的浓度为30-80mM。Preferably, the concentration of stachyose in the reaction solution is 30-80mM. 5.根据权利要求4所述的反应液,其特征在于,所述反应液还包括缓冲液、金属盐离子、去垢剂、ATP、dATP和dNTP。5. The reaction solution according to claim 4, characterized in that, the reaction solution further comprises buffer, metal salt ions, detergent, ATP, dATP and dNTP. 6.根据权利要求5所述的反应液,其特征在于,所述缓冲液包括三羟甲基氨基甲烷醋酸盐、三羟甲基氨基甲烷盐酸盐或4-羟乙基哌嗪乙磺酸中的任意一种或至少两种的组合;6. reaction solution according to claim 5, is characterized in that, described damping fluid comprises Tris hydroxymethyl amino methane acetate, tris hydroxymethyl amino methane hydrochloride or 4-hydroxyethylpiperazine ethyl sulfonate Any one or a combination of at least two of the acids; 优选地,所述反应液中三羟甲基氨基甲烷醋酸盐的含量为50-200mM,pH为7-8.5;Preferably, the content of Tris in the reaction solution is 50-200mM, and the pH is 7-8.5; 优选地,所述反应液中三羟甲基氨基甲烷盐酸盐的含量为100-150mM,pH为7-9;Preferably, the content of Tris hydrochloride in the reaction solution is 100-150mM, and the pH is 7-9; 优选地,所述反应液中4-羟乙基哌嗪乙磺酸的含量为100-180mM,pH为7-9。Preferably, the content of 4-hydroxyethylpiperazineethanesulfonic acid in the reaction solution is 100-180 mM, and the pH is 7-9. 7.根据权利要求5或6所述的反应液,其特征在于,所述金属盐离子包括CaCl2、MgCl2、ZnCl2、NaCl或KCl中的任意一种或至少两种的组合;7. The reaction solution according to claim 5 or 6, wherein the metal salt ions include any one or a combination of at least two of CaCl 2 , MgCl 2 , ZnCl 2 , NaCl or KCl; 优选地,所述反应液中CaCl2的含量为15-50mM;Preferably, the content of CaCl in the reaction solution is 15-50mM; 优选地,所述反应液中MgCl2的含量为35-200mM;Preferably, the content of MgCl in the reaction solution is 35-200mM; 优选地,所述反应液中ZnCl2的含量为20-80mM;Preferably, the ZnCl content in the reaction solution is 20-80mM; 优选地,所述反应液中NaCl的含量为20-200mM;Preferably, the content of NaCl in the reaction solution is 20-200mM; 优选地,所述反应液中KCl的含量为30-80mM。Preferably, the content of KCl in the reaction solution is 30-80mM. 8.根据权利要求5-7中任一项所述的反应液,其特征在于,所述所述去垢剂包括DTT、TritonⅩ-100、Tween-20或NP-40中的任意一种或至少两种的组合;8. The reaction solution according to any one of claims 5-7, characterized in that, the detergent comprises any one of DTT, TritonX-100, Tween-20 or NP-40 or at least a combination of the two; 优选地,所述反应液中DTT的含量为10-50mM;Preferably, the content of DTT in the reaction solution is 10-50mM; 优选地,所述反应液中TritonⅩ-100的含量为0.1-1%;Preferably, the content of TritonX-100 in the reaction solution is 0.1-1%; 优选地,所述反应液中Tween-20的含量为0.01-1%;Preferably, the content of Tween-20 in the reaction solution is 0.01-1%; 优选地,所述反应液中NP-40的含量为0.01-1%;Preferably, the content of NP-40 in the reaction solution is 0.01-1%; 优选地,所述反应液中dATP的含量为0.2-8mM,更优选为2-4mM;Preferably, the content of dATP in the reaction solution is 0.2-8mM, more preferably 2-4mM; 优选地,所述反应液中dNTP的含量为0.02-2mM,更优选为0.02-1mM;Preferably, the content of dNTP in the reaction solution is 0.02-2mM, more preferably 0.02-1mM; 优选地,所述反应液中ATP的含量为5-15mM。Preferably, the content of ATP in the reaction solution is 5-15mM. 9.一种构建测序文库的方法,其特征在于,所述方法包括:将靶核酸加入如权利要求1-3中任一项所述的酶组合物和4-8中任一项所述的反应液的混合液中,孵育,进行靶核酸的片段化、末端修复、5’磷酸化和3’加A尾。9. A method for constructing a sequencing library, characterized in that the method comprises: adding target nucleic acid to the enzyme composition according to any one of claims 1-3 and the enzyme composition according to any one of claims 4-8 Incubate in the mixture of reaction solution to carry out fragmentation of target nucleic acid, end repair, 5' phosphorylation and 3' A tailing. 10.一种用于构建测序文库的试剂盒,其特征在于,所述试剂盒包括权利要求1-3中任一项所述的酶组合物或4-8中任一项所述的反应液;10. A kit for constructing a sequencing library, characterized in that the kit includes the enzyme composition according to any one of claims 1-3 or the reaction solution according to any one of claims 4-8 ; 优选地,所述试剂盒还包括测序接头和连接反应试剂。Preferably, the kit also includes sequencing adapters and ligation reagents.
CN202310263158.7A 2023-03-17 2023-03-17 A low-preference DNA fragmentation enzyme composition and its reaction solution Pending CN116286726A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310263158.7A CN116286726A (en) 2023-03-17 2023-03-17 A low-preference DNA fragmentation enzyme composition and its reaction solution

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310263158.7A CN116286726A (en) 2023-03-17 2023-03-17 A low-preference DNA fragmentation enzyme composition and its reaction solution

Publications (1)

Publication Number Publication Date
CN116286726A true CN116286726A (en) 2023-06-23

Family

ID=86830151

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310263158.7A Pending CN116286726A (en) 2023-03-17 2023-03-17 A low-preference DNA fragmentation enzyme composition and its reaction solution

Country Status (1)

Country Link
CN (1) CN116286726A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118147274A (en) * 2024-03-23 2024-06-07 天根生化科技(北京)有限公司 Fragmenting enzyme reaction system for reducing quantity of hairpin structures formed by DNA interruption and DNA library construction method

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110236412A1 (en) * 2008-09-24 2011-09-29 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
US20160289723A1 (en) * 2015-03-30 2016-10-06 Rubicon Genomics, Inc. Methods and compositions for repair of dna ends by multiple enzymatic activities
CN111876525A (en) * 2020-07-08 2020-11-03 广州再生医学与健康广东省实验室 gRNA, primer and kit for detecting SARS-CoV-2
CN113337487A (en) * 2021-02-09 2021-09-03 南京诺唯赞生物科技股份有限公司 Enzyme composition for nucleic acid fragmentation and application thereof
CN114606575A (en) * 2020-12-03 2022-06-10 广东菲鹏生物有限公司 Compositions and library construction methods
CN114934030A (en) * 2021-03-25 2022-08-23 山东大学 High-specificity Taq DNA polymerase variant and application thereof in genome editing and/or gene mutation detection

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110236412A1 (en) * 2008-09-24 2011-09-29 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
US20160289723A1 (en) * 2015-03-30 2016-10-06 Rubicon Genomics, Inc. Methods and compositions for repair of dna ends by multiple enzymatic activities
CN111876525A (en) * 2020-07-08 2020-11-03 广州再生医学与健康广东省实验室 gRNA, primer and kit for detecting SARS-CoV-2
CN114606575A (en) * 2020-12-03 2022-06-10 广东菲鹏生物有限公司 Compositions and library construction methods
CN113337487A (en) * 2021-02-09 2021-09-03 南京诺唯赞生物科技股份有限公司 Enzyme composition for nucleic acid fragmentation and application thereof
CN114934030A (en) * 2021-03-25 2022-08-23 山东大学 High-specificity Taq DNA polymerase variant and application thereof in genome editing and/or gene mutation detection

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118147274A (en) * 2024-03-23 2024-06-07 天根生化科技(北京)有限公司 Fragmenting enzyme reaction system for reducing quantity of hairpin structures formed by DNA interruption and DNA library construction method

Similar Documents

Publication Publication Date Title
US20240352507A1 (en) Method for increasing throughput of single molecule sequencing by concatenating short dna fragments
CN102181943B (en) Paired-end library construction method and method for sequencing genome by using library
CN112313241B (en) Sensitive in vitro assays for substrate preference and site of nucleic acid binding, modification, and cleavage agents
CN106192021B (en) Method for constructing series connection RAD [restriction-site-associated DNA (deoxyribonucleic acid)] tag sequencing libraries
CN105603535B (en) Construct the kit and method of DNA library
US20220033811A1 (en) Method and kit for preparing complementary dna
CN107002292A (en) A method and reagents for constructing a nucleic acid double-linker single-stranded circular library
EP3674419A1 (en) Probe and method applying the same for enriching target region in high-throughput sequencing
CN110157785A (en) A single-cell RNA sequencing library construction method
WO2021253372A1 (en) High-compatibility pcr-free library building and sequencing method
CN116043337A (en) DNA methylation marker screening kit and method
CN112359093A (en) Method and kit for preparing and expressing and quantifying free miRNA library in blood
CN116875658A (en) Deoxyribozyme and method for detecting mRNA capping rate
Chen et al. In silico design of linear DNA for robust cell-free gene expression
CN116286726A (en) A low-preference DNA fragmentation enzyme composition and its reaction solution
US20180305683A1 (en) Multiplexed tagmentation
CN110747514A (en) High-throughput single-cell small RNA library construction method
CN103805706A (en) Quadruple fluorescence quantitative kit for rapid detection of SNP (single nucleotide polymorphism) loci
WO2020005159A1 (en) Method for detection and quantification of genetic alterations
CN110331141B (en) Mutant SSO7d SSB and application thereof
CN116497019A (en) Transcription buffer solution capable of improving in-vitro synthesized RNA yield and transcription reaction system
CN115386623A (en) Method and kit for detecting base editor editing sites
CN117402961B (en) Primer, kit and method for rapidly detecting chromosome aneuploidy before embryo implantation
US20230193375A1 (en) Method for the detection and quantification of genetic alterations
CN115537419B (en) A uridine diphosphate nucleic acid aptamer and its screening method and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination